Leslie J. Williams is a seasoned biotechnology CEO and board director with more than 25 years of experience building and leading high-growth life science companies. Her leadership spans company formation, translational science, clinical development, commercialization, and corporate strategy, guiding organizations from early scientific vision through clinical execution, strategic partnerships, and exits.

Ms. Williams has held executive and board roles across multiple biotechnology companies and therapeutic areas, including HC Bioscience, ImmusanT, Ventaira Pharmaceuticals, and INO Therapeutics. She is currently President & Chief Executive Officer of DaCapo Brainscience, where she leads a mission-driven team focused on advancing new medicines for patients with neurodegenerative disease.

She is widely recognized for her leadership in translational and immunology-focused biotechnology, including her tenure as Chief Executive Officer of ImmusanT, where she helped advance novel therapeutic approaches for immune-mediated diseases. Throughout her career, Ms. Williams has emphasized building high-performing teams, shaping development strategies, and aligning scientific innovation with regulatory and commercial pathways.

Ms. Williams brings deep expertise in corporate governance, investor engagement, and long-term value creation with a track record of leading science-driven companies as they scale. She is known for her thoughtful, mission-driven leadership and her commitment to advancing transformative medicines that meaningfully improve patients’ lives.